SSRI CHINA news

According to PatientsMap CN 2019 data which asks doctors about sales reps that have visited them in the past month for 64 pharmaceutical companies, approximately 1/3 of the 12,000 physicians in China have answered that they met a sales rep from Pfizer and AstraZeneca in the past month.  Below table shows the top 10 pharmaceutical companies with the highest sales rep visitation rates overall.

Compared to 2018 data, while the top 4 companies remain unchanged, we see more domestic pharma companies in the top 10 (2 companies in 2018 vs. 4 companies in 2019), and CTTQ pharmaceutical moved from 8^th to 5^th.  In particular for the oncology area, there are 5 domestic pharma companies in the top 10 sales rep visits, with the top being a domestic company Hengrui with 50.2% sales rep visitation rate. This may suggest that the domestic companies are starting to enhance their sales force activities.

The highest ranked Japanese companies were Eisai (25th with 7.2%), Takeda (27^th with 5.3%) and Daiichi Sankyo (29^th with 4.9%).

For more information about PatientsMap CN 2019, please see below: